Latest filing published 02 Dec 2022 for Dianthus Therapeutics, Inc. /DE/, €2,731.
Insider track record
Kristen Stants: trading record in brief
Kristen Stants, listed as senior executive, appears in our data through filings on Dianthus Therapeutics, Inc. /DE/ shares, published by SEC (Form 4). We count 4 filings; the first trade dates from 14 September 2021 and the latest from 30 November 2022.
On the market, this insider has only sold: 1 sale, €33k in total. Other entries cover 3 share grants.
The record was last updated on 2 December 2022 with a share grant (€2,731) in Dianthus Therapeutics, Inc. /DE/. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Kristen Stants
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,000 shares@ US$0.947.1% of flowCommon StockSEC:0000899243-22-037424:0
- 3,000 shares@ US$0.997.2% of flowCommon StockSEC:0000899243-22-021186:0
- 5,736 shares@ US$6.7385.6% of flowCommon StockSEC:0000899243-21-036604:0
- 20,000 shares0Common StockSEC:0000899243-21-036341:0
4 of 3 declarations
